Resolution Therapeutics

Resolution Therapeutics CEO, Amir Hefni and VP of Research Operations, Lara Campana, will attend The Global Cell & Gene Therapy Summit 2024 in Boston, MA, from July 8th to 10th.   Today, Amir will present 'Pioneering Macrophage Cell Therapy in End Stage Liver Disease' at 12:50PM EST. Following this, Lara will chair the session 'Advancements in Cell and Stem Cell-based Therapies' at 14:10PM EST alongside Anand Srivastava, MS, PhD from the Global Institute of Stem Cell Therapy and Research. This session will consist of presentations from John Lu, Ruby Yanru Chen-Tsai, Demet (Dee) S., Zhengpeng (Jason) Wan, Jun Yung Woo, Anastasia Kremer, and Qi Zhao.   If you are attending the summit, get in touch to meet a member of the Resolution team!   #GeneTherapy #CellTherapy #Macrophages

Did you miss our R&D Webinar on Resolution Therapeutics novel discovery platform for engineered macrophage cell therapy, including insights on data presented at #EASL2024? Catch up on all the insightful presentations and discussions from our management team, including CEO, Amir Hefni and CDO, Clifford Brass, as well as expert hepatologist, Arun Sanyal, by watching it here: https://lnkd.in/e-KWGDJ4 Thank you to everyone who came along! 

Our CEO, Amir Hefni, attended #ONHelix2024 today and presented Resolution Therapeutics as a ‘Company to watch’ highlighting its pioneering macrophage cell therapy for end stage liver disease.   Amir also took part in the ‘New Horizons for Therapeutic Modalities’ panel moderated by Hugh Nuthall, Eli lilly, alongside Benjamin Taylor, AstraZeneca, Kia Pedersen, Pelago Bioscience AB, Madeleine Wakeling, Harness Therapeutics and DAVIDE DE LUCREZIA, Officinae Bio. This panel of esteemed life science leaders discussed the importance of early conversations to speed up optimisation with CROs and with the FDA/MHRA.

We're going LIVE TODAY! Join us at 12.30 BST / 7.30 EDT for our R&D webinar. Get ready to dive into the latest insights on macrophage cell therapies to treat end stage liver disease. Our management team and expert hepatologist, Arun Sanyal, M.D., are geared up to discuss data presented at #EASL2024 that provides a clear clinical proof of concept for macrophage cell therapy as an effective and durable treatment for advanced liver cirrhosis as well as Resolution Therapeutics’ innovative macrophage cell therapy platform. Join the webinar here: https://lnkd.in/ecTGYD-w

We're going LIVE TODAY! Join us at 12.30 BST / 7.30 EDT for our R&D webinar. Get ready to dive into the latest insights on macrophage cell therapies to treat end stage liver disease. Our management team and expert hepatologist, Arun Sanyal, M.D., are geared up to discuss data presented at #EASL2024 that provides a clear clinical proof of concept for macrophage cell therapy as an effective and durable treatment for advanced liver cirrhosis as well as Resolution Therapeutics’ innovative macrophage cell therapy platform. Join the webinar here: https://lnkd.in/ecTGYD-w

We're going LIVE TODAY! Join us at 12.30 BST / 7.30 EDT for our R&D webinar. Get ready to dive into the latest insights on macrophage cell therapies to treat end stage liver disease. Our management team and expert hepatologist, Arun Sanyal, M.D., are geared up to discuss data presented at #EASL2024 that provides a clear clinical proof of concept for macrophage cell therapy as an effective and durable treatment for advanced liver cirrhosis as well as Resolution Therapeutics’ innovative macrophage cell therapy platform. Join the webinar here: https://lnkd.in/ecTGYD-w

Join us TOMORROW, Friday 28th June at 12.30 BST / 7.30 EDT, for presentations highlighting the differentiated opportunity for macrophage cell therapies to deeply and durably treat end-stage liver disease.   Our management team and expert hepatologist, Arun Sanyal, M.D., will be sharing insights from recent presentations at #EASL2024 and answering questions during a live Q&A!   Register now and submit your questions in advance using the link: https://lnkd.in/ecTGYD-w

We are delighted to announce that Resolution Therapeutics has received Medicines and Healthcare products Regulatory Agency approval to commence a Phase I/II EMERALD study for lead candidate RTX001, an engineered autologous macrophage cell therapy to treat end stage liver disease.   The study will investigate the safety and efficacy of RTX001 in patients with decompensated liver cirrhosis and is anticipated to start recruiting patients as early as Q3 2024. This #MHRA approval is the next step for Resolution becoming a fully clinical-stage biopharmaceutical company.   To learn more about Resolution and the development of macrophage cell therapies for end stage liver disease, join our R&D webinar TOMORROW at 12.30 BST / 7.30 EDT by registering through the link here: https://lnkd.in/ecTGYD-w   Read the full press release in the comments below.   #Macrophage #CellTherapy #ESLD

Do you know there are very limited treatment options for patients with inflammatory organ diseases? In this Sejelas CEO Interview series, we hear from Amir Hefni, the CEO of Resolution Therapeutics. The team is on a mission to transform the outcomes of patients with inflammatory organ disease by pioneering macrophage cell therapy. Read the full article here: https://lnkd.in/g_pm63se #biotech #ESLD #liver #therapeutics #sejelas #ceo #interviewseries

Just a few more days until our upcoming R&D webinar!   Join us this Friday 28th June at 12.30 BST / 7.30 EDT for presentations from the Resolution Therapeutics management team and key opinion leader and expert hepatologist, Arun Sanyal, M.D..   Data presented at #EASL2024 reconfirming clear clinical proof of concept for macrophage cell therapy as an effective and durable treatment for advanced liver cirrhosis will be presented.   They will also delve into insights on Resolution's discovery platform for engineered macrophage cell therapy and discuss the unmet need and current treatment landscape for liver disease.   Register and submit your questions in advance here: https://lnkd.in/ecTGYD-w